Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kineta Inc KA

Healthcare Biotechnology
Kineta, Inc. is a clinical-stage biotechnology company. The Company has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a... see more

Recent & Breaking News (NDAQ:KA)

STOCKHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Proteostasis Therapeutics, Inc. - PTI

PR Newswire August 28, 2020

INVESTIGATION ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders are Encouraged to Contact the Firm - PTI, CGIX, YIN, NETE

ACCESSWIRE IA August 27, 2020

Moore Kuehn Encourages MXIM, CGIX, PTI, and DCOM Investors to Contact Law Firm

GlobeNewswire August 27, 2020

PROTEOSTASIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Proteostasis Therapeutics, Inc. - PTI

Business Wire August 26, 2020

SHAREHOLDER ALERT: WeissLaw LLP Investigates Proteostasis Therapeutics, Inc.

PR Newswire August 25, 2020

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Proteostasis Therapeutics, Inc.

Business Wire August 25, 2020

PROTEOSTASIS THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger

Newsfile August 25, 2020

PROTEOSTASIS MERGER INVESTIGATION: Halper Sadeh LLP Announces Investigation Into Whether The Merger of Proteostasis Therapeutics, Inc. is Fair to Shareholders; Investors are Encouraged to Contact The Firm

PR Newswire August 25, 2020

PROTEOSTASIS THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PTI and Encourages Investors to Contact the Firm

GlobeNewswire August 24, 2020

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Proteostasis Therapeutics, Inc. and Yumanity Therapeutics, Inc. is Fair to PTI Shareholders

Newsfile August 24, 2020

Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement

PR Newswire August 24, 2020

Proteostasis Therapeutics Reports Second Quarter 2020 Financial Results

PR Newswire August 6, 2020

Proteostasis Therapeutics Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

PR Newswire June 5, 2020

Proteostasis Therapeutics Announces In Vitro Data for PTI-129 as Potential Treatment Candidate for COVID-19

PR Newswire June 1, 2020

Proteostasis Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

PR Newswire May 15, 2020

Proteostasis Therapeutics to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

PR Newswire May 13, 2020

Proteostasis Therapeutics Announces Completion of Scientific Advice Meeting with the Dutch Medicines Evaluation Board

PR Newswire April 13, 2020

Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update

PR Newswire March 10, 2020

Proteostasis Therapeutics Announces New Publication on the Mechanism of Action of a Novel Class of CFTR Modulators Called Amplifiers in the Journal of Cystic Fibrosis

PR Newswire February 25, 2020

Proteostasis Therapeutics and CF Europe Announce Completion of Patient Enrollment for CHOICES, the First-Ever Personalized Medicine-Based Study in Cystic Fibrosis

PR Newswire February 24, 2020